# DSGN (Design Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Design Therapeutics, Inc. reported $0 in revenue and a net loss of $74.09M for the trailing twelve months ended September 30, 2026.

- Canonical: https://convexityos.com/fundamentals/DSGN
- Markdown: https://convexityos.com/fundamentals/DSGN.md
- SEC CIK: 0001807120
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:33 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001807120&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $0 | Sep 30, 2026 |
| Operating Income | TTM | -$82.28M | Operating profit |
| Net Income | TTM | -$74.09M | GAAP bottom line |
| Diluted EPS | TTM | -$1.18 | Split-adjusted |
| Free Cash Flow | TTM | -$59.37M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $208.6M | Total debt: $2.51M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | -- | -- | -- | $226K |
| Research & Development | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M |
| Total Operating Expenses | $79.47M | $62.38M | $78.19M | $67.59M | $35.83M | $8.56M |
| **Operating Income** | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M | -$8.33M |
| **EBITDA** | -$78.84M | -$61.79M | -$77.65M | -$67.19M | -$35.70M | -$8.32M |
| Interest Income | $9.68M | $12.79M | $11.33M | -- | -- | -- |
| Income Tax Expense | $0 | $0 | -- | -- | -- | -- |
| **Net Income** | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M |
| Basic EPS | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
| **Diluted EPS** | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
| Basic Shares Outstanding | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | 15.8M |
| Diluted Shares Outstanding | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | 15.8M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -- |
| Research & Development | $16.93M | $16.39M | $14.38M | $13.43M | $14.59M | $15.74M | $15.38M | $12.16M |
| Total Operating Expenses | $22.23M | $22.18M | $19.71M | $18.17M | $19.31M | $21.57M | $20.42M | $16.69M |
| **Operating Income** | -$22.23M | -$22.18M | -$19.71M | -$18.17M | -$19.31M | -$21.57M | -$20.42M | -$16.69M |
| **EBITDA** | -$22.09M | -$22.03M | -$19.55M | -$18.01M | -$19.16M | -$21.42M | -$20.26M | -$16.55M |
| Interest Income | $1.94M | $2.01M | $2.07M | $2.17M | $2.31M | $2.49M | $2.70M | $3.04M |
| **Net Income** | -$20.29M | -$20.16M | -$17.64M | -$16.00M | -$17.00M | -$19.08M | -$17.71M | -$13.65M |
| Basic EPS | -$0.32 | -$0.32 | -$0.29 | -- | -$0.30 | -$0.34 | -$0.31 | -- |
| **Diluted EPS** | -$0.32 | -$0.32 | -$0.29 | -- | -$0.30 | -$0.34 | -$0.31 | -- |
| Basic Shares Outstanding | 63.0M | 62.5M | 61.4M | -- | 57.0M | 56.9M | 56.8M | -- |
| Diluted Shares Outstanding | 63.0M | 62.5M | 61.4M | -- | 57.0M | 56.9M | 56.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $16.86M | $22.56M | $21.20M | $26.50M | $298.6M | $2.38M |
| Short-Term Investments | $203.0M | $222.9M | $260.6M | $303.9M | $85.50M | $33.71M |
| **Cash & Short-Term Investments** | $219.8M | $245.5M | $281.8M | $330.4M | $384.1M | $36.09M |
| Other Current Assets | -- | -- | -- | -- | $7.0K | $25K |
| **Total Current Assets** | $223.8M | $248.0M | $284.6M | $335.1M | $385.4M | $36.23M |
| Property, Plant & Equipment, Net | $981K | $1.41M | $1.69M | $1.95M | $1.51M | $71K |
| **Total Non-Current Assets** | $2.42M | $4.05M | $5.06M | $6.02M | $5.12M | $283K |
| **Total Assets** | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M | $36.52M |
| Accounts Payable | $2.31M | $2.19M | $1.94M | $3.02M | $1.62M | $1.40M |
| **Total Current Liabilities** | $13.05M | $8.46M | $9.62M | $10.78M | $5.28M | $2.33M |
| Other Non-Current Liabilities | -- | -- | -- | -- | -- | $145K |
| **Total Non-Current Liabilities** | $645K | $1.53M | $2.33M | $3.05M | $3.14M | $145K |
| **Total Liabilities** | $13.70M | $10.00M | $11.96M | $13.83M | $8.43M | $2.48M |
| **Total Debt (incl. Leases)** | $1.53M | $2.33M | $3.05M | $3.69M | $3.63M | -- |
| Common Stock | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $1.0K |
| Retained Earnings | -$297.0M | -$227.2M | -$177.6M | -$110.8M | -$47.46M | -$11.92M |
| Accumulated Other Comp. Income | $403K | $475K | $62K | -$3.36M | -$244K | $156K |
| **Total Stockholders' Equity** | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | -$11.31M |
| Total Equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M | -$11.31M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $15.25M | $12.91M | $12.77M | $16.86M | $15.09M | $19.70M | $13.67M | $22.56M |
| Short-Term Investments | $193.4M | $194.5M | $210.1M | $203.0M | $190.9M | $196.6M | $216.0M | $222.9M |
| **Cash & Short-Term Investments** | $208.6M | $207.4M | $222.8M | $219.8M | $206.0M | $216.3M | $229.7M | $245.5M |
| **Total Current Assets** | $214.0M | $212.0M | $227.0M | $223.8M | $209.0M | $219.8M | $233.6M | $248.0M |
| Property, Plant & Equipment, Net | $573K | $694K | $824K | $981K | $1.10M | $1.26M | $1.38M | $1.41M |
| **Total Non-Current Assets** | $2.85M | $3.12M | $3.39M | $2.42M | $2.74M | $3.09M | $3.83M | $4.05M |
| **Total Assets** | $216.8M | $215.1M | $230.4M | $226.2M | $211.8M | $222.9M | $237.5M | $252.1M |
| Accounts Payable | $2.08M | $3.14M | $2.28M | $2.31M | $1.91M | $1.01M | $3.18M | $2.19M |
| **Total Current Liabilities** | $12.75M | $11.24M | $10.19M | $13.05M | $11.17M | $8.75M | $8.24M | $8.46M |
| **Total Non-Current Liabilities** | $1.86M | $2.03M | $2.20M | $645K | $877K | $1.10M | $1.32M | $1.53M |
| **Total Liabilities** | $14.61M | $13.27M | $12.39M | $13.70M | $12.05M | $9.85M | $9.56M | $10.00M |
| **Total Debt (incl. Leases)** | $2.51M | $2.66M | $2.73M | $1.53M | $1.74M | $1.95M | $2.14M | $2.33M |
| Common Stock | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained Earnings | -$355.1M | -$334.8M | -$314.6M | -$297.0M | -$281.0M | -$264.0M | -$244.9M | -$227.2M |
| Accumulated Other Comp. Income | -$1.68M | -$771K | -$268K | $403K | $358K | $305K | $450K | $475K |
| **Total Stockholders' Equity** | $202.2M | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M | $242.1M |
| Total Equity | $202.2M | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M | $242.1M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M |
| Depreciation & Amortization | $622K | $596K | $537K | $406K | $129K | $5.0K |
| Stock-Based Compensation | $14.55M | $13.07M | $13.09M | $10.93M | $4.69M | $450K |
| **Operating Cash Flow** | -$54.36M | -$43.10M | -$58.56M | -$51.32M | -$29.38M | -$8.67M |
| Capital Expenditure | -$193K | -$340K | -$256K | -$918K | -$1.54M | -$76K |
| **Free Cash Flow** | -$54.55M | -$43.45M | -$58.82M | -$52.23M | -$30.91M | -$8.74M |
| Purchases of Investments | -$291.8M | -$230.2M | -$224.7M | -$313.0M | -$86.26M | -$55.59M |
| **Investing Cash Flow** | $22.91M | $43.95M | $52.54M | -$221.0M | -$53.64M | -$33.56M |
| Common Stock Issued | $24.85M | $0 | -- | -- | -- | -- |
| **Financing Cash Flow** | $25.74M | $513K | $724K | $235K | $379.2M | $44.53M |
| **Net Change in Cash** | -$5.71M | $1.36M | -$5.30M | -$272.1M | $296.2M | $2.30M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$20.29M | -$20.16M | -$17.64M | -$16.00M | -$17.00M | -$19.08M | -$17.71M | -$13.65M |
| Depreciation & Amortization | $136K | $151K | $157K | $156K | $155K | $152K | $159K | $149K |
| Stock-Based Compensation | $4.05M | $3.87M | $3.92M | $3.44M | $3.59M | $3.98M | $3.54M | $3.47M |
| **Operating Cash Flow** | -$15.38M | -$15.52M | -$16.43M | -$11.97M | -$11.16M | -$14.44M | -$16.79M | -$9.86M |
| Capital Expenditure | -$15K | -$21K | $0 | -$34K | $0 | -$87K | -$72K | $0 |
| **Free Cash Flow** | -$15.39M | -$15.54M | -$16.43M | -$12.00M | -$11.16M | -$14.53M | -$16.86M | -$9.86M |
| Purchases of Investments | -$29.80M | -$12.42M | -$52.59M | -$87.62M | -$78.08M | -$39.53M | -$86.55M | -$64.37M |
| **Investing Cash Flow** | $189K | $15.06M | -$7.59M | -$11.58M | $6.51M | $20.12M | $7.87M | $1.83M |
| Common Stock Issued | $17.26M | $0 | $19.91M | $24.85M | $0 | $0 | $0 | -- |
| **Financing Cash Flow** | $17.53M | $605K | $19.93M | $25.32M | $37K | $361K | $23K | $263K |
| **Net Change in Cash** | $2.35M | $137K | -$4.09M | $1.77M | -$4.62M | $6.04M | -$8.90M | -$7.76M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -- | -3685.8% |
| **Net Profit Margin** | -- | -- | -- | -- | -- | -3663.7% |
| Return on Equity (ROE) | -32.8% | -20.5% | -24.1% | -19.3% | -9.3% | -- |
| Return on Assets (ROA) | -30.9% | -19.7% | -23.1% | -18.6% | -9.1% | -22.7% |
| Current Ratio | 17.14x | 29.31x | 29.58x | 31.10x | 72.96x | 15.55x |
| Quick Ratio | 16.84x | 29.01x | 29.29x | 30.66x | 72.70x | 15.49x |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | -- |
| 5Y Revenue / Share Growth | -100.0% | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -36.6% | -35.1% | -32.0% | -32.8% | -33.8% | -29.8% | -24.7% | -20.5% |
| Return on Assets (ROA) | -34.2% | -32.9% | -30.3% | -30.9% | -31.8% | -28.5% | -23.7% | -19.7% |
| Current Ratio | 16.78x | 18.86x | 22.28x | 17.14x | 18.71x | 25.13x | 28.37x | 29.31x |
| Quick Ratio | 16.36x | 18.45x | 21.86x | 16.84x | 18.44x | 24.73x | 27.89x | 29.01x |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
